| Introduction | For Patients | For Science | For Society | Looking Ahead Delivering on a Scale Today, CSL provides a diverse portfolio of lifesaving medicines and vaccines to patients in more than 120 countries worldwide. ~6.6k people living with haemophilia A & B ~1.3m pregnant women with rhesus incompatibility ~9.0k people living with protein deficiencies (including hereditary angioedema (HAE), alpha-1 antitrypsin deficiency (AATD)) ~4.1m people whose health was threatened by sepsis, cirrhosis, hypoalbuminaemia and a range of other conditions $22.3m supporting product access around the world ~167k people living with autoimmune diseases and immune deficiencies In FY26, our medicines were used in the treatment of: 10 | CSL IMPACT REPORT 2026
RkJQdWJsaXNoZXIy MjE2NDg3